We are in the business of creating new drug leads. Utilizing our proprietary protein re-engineering capabilities, Molecular LogiX evaluates specific modifications of clinically-relevant proteins to create new therapeutic properties.

Our efforts are focused on the development of new “Dominant Negative Ligands” for the treatment of important diseases. Our primary work is devoted to the development of a new “Pan-HER Anti-Cancer Ligand” to treat tumors that have become resistant to current molecular targeting therapies.